Medicine

Drug Eluting Stents, Bare Metal Stents: No Survival Difference

Stefan James
Stefan James
Raymond Gibbons
Raymond Gibbons

REFERENCE: Hot Line 1 Sunday 11:00 2 Sept, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
STEFAN JAMES, Uppsala Clinical Research Centre, Sweden
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester MN

Another year’s results of the long term outcome of using drug-eluting stents as compared with bare-metal stents from Sweden reveal that there is no longer an increased risk of late mortality when using drug-eluting stents according to Stefan James of Uppsala Clinical Research Centre. He suggested that improvements in technique have helped reduce the risk of death or myocardial infarction associated with using drug-eluting stents nevertheless the risk of blood clots still remains. Overall survival of patients was found to be the similar for both categories of stent.
Nicola Soloman interviewed Stefan James after his presentation at the European Society of Cardiology meeting in Vienna. Raymond Gibbons, president of the American Heart Association, added his comments.

Similar Interviews

  • Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI
  • Laura Mauri Raymond Gibbons REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November,

  • Audio Journal of Cardiovascular Medicine: September 8th 2006
  • Christoph Kaiser

  • Audio Journal of Cardiovascular Medicine: Sirolimus-Eluting Better Than Uncoated Stents for Primary Angioplasty
  • CHRISTIAN SPAULDING, Cochin Hospital, Paris REFERENCE: N Engl J Med 2006;355:1093, 1105,1169 Two leading articles in the same edition of the New

    Post a comment

    Subscribe to Audio Medica Podcast